Many randomized, phase 3 studies have shown that for EGFR‐positive lung cancer patients, targeted drugs, such as gefitinib and osimertinib, can significantly prolong disease‐free survival and improve prognosis in patients.18 Here, EGFR is linked to lung carcinoma.